Vaccination against a hit-and-run viral cancer

Journal of General Virology

Volumn 91, Issue 9, 2010, Pages 2176-2185

  Stevenson, Philip G ^a   May, Janet S ^a   Connor, Viv ^a   Efstathiou, Stacey ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE CONTROL; GAMMAHERPESVIRINAE; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; VACCINATION; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION;

ANIMALS; BASE SEQUENCE; CANCER VACCINES; DNA PRIMERS; GENES, P53; GENES, RAS; GENOME, VIRAL; HERPESVIRIDAE INFECTIONS; HUMANS; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTAGENESIS, INSERTIONAL; MUTATION; RHADINOVIRUS; SARCOMA, EXPERIMENTAL; TUMOR VIRUS INFECTIONS; VACCINATION; VIRAL VACCINES;

MURID HERPESVIRUS 4; MUS;

EID: 77956282571     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.023507-0     Document Type: Article

References (47)

1. Adler, H., Messerle, M., Wagner, M. & Koszinowski, U. H. (2000). Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol 74, 6964-6974. (Pubitemid 30470679)
2. Ambinder, R. F. (2000). Gammaherpesviruses and "hit-and-run" oncogenesis. Am J Pathol 156, 1-3.
3. Bennett, N. J., May, J. S. & Stevenson, P. G. (2005). Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol 3, e120.
4. Blumberg, B. S. (1997). Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci U S A 94, 7121-7125. (Pubitemid 27345277)
5. Boname, J. M., Coleman, H. M., May, J. S. & Stevenson, P. G. (2004). Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant. J Gen Virol 85, 131-135.
6. Bowden, R. J., Simas, J. P., Davis, A. J. & Efstathiou, S. (1997). Murine gammaherpesvirus 68 encodes tRNA-like sequences that are expressed during latency. J Gen Virol 78, 1675-1687.
7. Carbone, A., Cesarman, E., Spina, M., Gloghini, A. & Schulz, T. F. (2009). HIV-associated lymphomas and gamma-herpesviruses. Blood 113, 1213-1224.
8. de Lima, B. D., May, J. S. & Stevenson, P. G. (2004). Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol 78, 5103-5112.
9. Deyrup, A. T. (2008). Epstein - Barr virus-associated epithelial and mesenchymal neoplasms. Hum Pathol 39, 473-483.
10. Dittmer, D. P., Hilscher, C. J., Gulley, M. L., Yang, E. V., Chen, M. & Glaser, R. (2008). Multiple pathways for Epstein - Barr virus episome loss from nasopharyngeal carcinoma. Int J Cancer 123, 2105-2112.
11. DuPage, M., Dooley, A. L. & Jacks, T. (2009). Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4, 1064-1072.
12. Efstathiou, S., Ho, Y. M. & Minson, A. C. (1990). Cloning and molecular characterization of the murine herpesvirus 68 genome. J Gen Virol 71, 1355-1364. (Pubitemid 20190472)
13. Fowler, P. & Efstathiou, S. (2004). Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73. J Gen Virol 85, 609-613.
14. Fowler, P., Marques, S., Simas, J. P. & Efstathiou, S. (2003). ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J Gen Virol 84, 3405-3416.
15. Frazer, I. H. (2004). Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4, 46-54. (Pubitemid 38084131)
16. Ganem, D. (2006). KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1, 273-296.
17. Gaspar, M., Gill, M. B., Lösing, J. B., May, J. S. & Stevenson, P. G. (2008). Multiple functions for ORF75c in murid herpesvirus-4 infection. PLoS One 3, e2781.
18. Hammerschmidt, W. & Sugden, B. (2004). Epstein - Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol Med 10, 331-336.
19. Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T. & Tuveson, D. A. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15, 3243-3248.
20. Janssen, K. P., Abal, M., El Marjou, F., Louvard, D. & Robine, S. (2005). Mouse models of K-ras-initiated carcinogenesis. Biochim Biophys Acta 1756, 145-154.
21. Kang, M. S., Lu, H., Yasui, T., Sharpe, A., Warren, H., Cahir- McFarland, E., Bronson, R., Hung, S. C. & Kieff, E. (2005). Epstein - Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci U S A 102, 820-825.
22. Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. (2000). Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14, 994-1004. (Pubitemid 30253007)
23. May, J. S., Coleman, H. M., Smillie, B., Efstathiou, S. & Stevenson, P. G. (2004). Forced lytic replication impairs host colonization by a latency-deficient mutant of murine gammaherpesvirus-68. J Gen Virol 85, 137-146.
24. Milho, R., Smith, C. M., Marques, S., Alenquer, M., May, J. S., Gillet, L., Gaspar, M., Efstathiou, S., Simas, J. P. & Stevenson, P. G. (2009). In vivo imaging of murid herpesvirus-4 infection. J Gen Virol 90, 21-32.
25. Moorman, N. J., Willer, D. O. & Speck, S. H. (2003). The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J Virol 77, 10295-10303.
26. Münz, C. (2004). Epstein - Barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med 199, 1301-1304.
27. Nicolaides, A., Huang, Y. Q., Li, J. J., Zhang, W. G. & Friedman-Kien, A. E. (1994). Gene amplification and multiple mutations of the K-ras oncogene in Kaposi's sarcoma. Anticancer Res 14, 921-926.
28. Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M. L., Ordóñez, G. R. & other authors (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
29. Proença, J. T., Coleman, H.M., Connor, V.,Winton, D. J. & Efstathiou, S. (2008). A historical analysis of herpes simplex virus promoter activation in vivo reveals distinct populations of latently infected neurones. J Gen Virol 89, 2965-2974.
30. Rickabaugh, T. M., Brown, H. J., Martinez-Guzman, D., Wu, T. T., Tong, L., Yu, F., Cole, S. & Sun, R. (2004). Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection. J Virol 78, 9215-9223. (Pubitemid 39096531)
31. Rickinson, A. B. & Moss, D. J. (1997). Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15, 405-431.
32. Rosa, G. T., Gillet, L., Smith, C. M., de Lima, B. D. & Stevenson, P. G. (2007). IgG Fc receptors provide an alternative infection route for murine gamma-herpesvirus-68. PLoS One 2, e560.
33. Shah, K.M. & Young, L. S. (2009). Epstein - Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin Microbiol Infect 15, 982-988.
34. Smith, G. A. & Enquist, L. W. (2000). A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis. Proc Natl Acad Sci U S A 97, 4873-4878.
35. Smith, C. M., Gill, M. B., May, J. S. & Stevenson, P. G. (2007). Murine gammaherpesvirus-68 inhibits antigen presentation by dendritic cells. PLoS One 2, e1048.
36. Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F. & Denis, M. (2007). Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein - Barr virus vaccine in healthy young adults. J Infect Dis 196, 1749-1753.
37. Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21, 70-71.
38. + T cells aids amplification of a latent γ-herpesvirus. Nat Immunol 3, 733-740.
39. Stevenson, P. G., Simas, J. P. & Efstathiou, S. (2009). Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4. J Gen Virol 90, 2317-2330.
40. Stewart, J. P., Usherwood, E. J., Ross, A., Dyson, H. & Nash, T. (1998). Lung epithelial cells are a major site of murine gamma-herpesvirus persistence. J Exp Med 187, 1941-1951. (Pubitemid 28285564)
41. Suárez, A. L. & van Dyk, L. F. (2008). Endothelial cells support persistent gammaherpesvirus 68 infection. PLoS Pathog 4, e1000152.
42. Sunil-Chandra, N. P., Efstathiou, S. & Nash, A. A. (1992). Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J Gen Virol 73, 3275-3279.
43. Sunil-Chandra, N. P., Arno, J., Fazakerley, J. & Nash, A. A. (1994). Lymphoproliferative disease in mice infected with murine gamma-herpesvirus 68. Am J Pathol 145, 818-826.
44. Tarakanova, V. L., Suarez, F., Tibbetts, S. A., Jacoby, M. A., Weck, K. E., Hess, J. L., Speck, S. H. & Virgin, H. W., IV (2005). Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB β2 microglobulin-deficient mice. J Virol 79, 14668-14679.
45. Thorley-Lawson, D. A. & Allday, M. J. (2008). The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6, 913-924.
46. Tibbetts, S. A., McClellan, J. S., Gangappa, S., Speck, S. H. & Virgin, H. W., IV (2003). Effective vaccination against long-term gamma-herpesvirus latency. J Virol 77, 2522-2529.
47. Yin, Y., Manoury, B. & Fahraeus, R. (2003). Self-inhibition of synthesis and antigen presentation by Epstein - Barr virus-encoded EBNA1. Science 301, 1371-1374. (Pubitemid 37075811)